第四代电子烟和燃烧式香烟的急性心血管影响:对降低危害的影响
Randy Nguyen1, Isabelle Ruedisueli1, Karishma Lakhani1
1Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States.
电子烟 (EC) 和烟草烟 (TC) 中的尼古丁会急剧增加心率和血压. 使用EC可能会带来心脏风险,质疑其降低伤害的作用.
科学领域:
- 心血管生理学心血管生理学
- 烟草和尼古丁研究研究
- 公共卫生 公共卫生
背景情况:
- 电子烟 (EC) 对于戒烟很受欢迎,但它们对心血管的影响仍在争论中.
- 了解ECs引起的急性血液动力学和心率变化 (HRV) 变化对公共健康至关重要.
- 之前的研究缺乏EC和传统烟草香烟 (TC) 在心血管参数上的直接比较.
研究的目的:
- 为了比较ECs与TCs在用户和非用户中的急性心血管影响 (心率,血压,HRV).
- 研究尼古丁与非尼古丁成分在不良心血管反应中的作用.
- 评估与EC使用相关的潜在心脏风险,特别是在减少危害的背景下.
主要方法:
- 110名参与者 (非用户,独家EC用户,TC/双用户) 接受了基线心血管测量.
- 参与者接触到第四代EC (含尼古丁或不含尼古丁),TC (含尼古丁或不含尼古丁) 或吸管对照.
- 暴露后测量了心率 (HR),血压 (BP) 和心率变化 (HRV).
主要成果:
- 与非尼古丁版本相比,含尼古丁的EC和TC显著增加了HR和BP.
- 单独使用EC的用户在尼古丁EC使用后显示HR,BP增加,HRV模式改变 (表明心脏交感活动增加).
- 从尼古丁-TCs和尼古丁-ECs中,TC/双重用户经历了类似的BP增加,但从TCs中,HR增加更大.
结论:
- 尼古丁似乎是来自EC和TC的急性不良心血管变化的主要驱动因素.
- 急性EC使用会诱导慢性EC使用者与心脏风险相关的异常HRV模式.
- 对EC和TC的类似血液动力学反应质疑EC在减少危害策略中的作用.
更多相关视频
08:39Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
Published on: August 25, 2018
10:44Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
相关概念视频
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
CNS Depressants: Alcohol and Nicotine
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
